CERT Certara, Inc.
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.…
Industry Peers
Health Information ServicesKey Statistics
About Certara (NASDAQ: CERT)
›
Certara (NASDAQ: CERT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Health Information Services industry, part of the Healthcare sector, and reports about 1,515 employees.
The shares were at 10.68 USD on 19 November 2026, down 5.2% over 52 weeks. Its 52-week range is 4.450 USD to 12.61 USD: the price is 15.3% below the high and 140.0% above the low.
Its market capitalisation is 1.63B USD.
Certara reports return on equity of -0.2%, an operating margin of 5.8% and revenue up 4.4% year over year.
Its debt exceeds its cash by 84.43M USD, a debt-to-equity ratio of 0.29. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 11 analysts cover the stock, with an average rating of Buy; their mean price target of 12.68 USD is 18.7% above the current price. The next earnings report is expected on 25 February 2027.